Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 19 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 57% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $394,475, and 13 were calls, valued at $1,274,461.
What's The Price Target?
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $370.0 to $1180.0 for Eli Lilly and Co during the past quarter.
Analyzing Volume & Open Interest
In today's trading context, the average open interest for options of Eli Lilly and Co stands at 383.39, with a total volume reaching 413.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly and Co, situated within the strike price corridor from $370.0 to $1180.0, throughout the last 30 days.
Eli Lilly and Co 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| LLY | CALL | TRADE | BULLISH | 01/16/26 | $1000.00 | $378.0K | 129 | 0 |
| LLY | PUT | TRADE | BEARISH | 08/16/24 | $700.00 | $229.2K | 7 | 60 |
| LLY | CALL | SWEEP | BULLISH | 01/16/26 | $370.00 | $200.0K | 9 | 5 |
| LLY | CALL | SWEEP | BEARISH | 03/15/24 | $730.00 | $158.0K | 1.0K | 104 |
| LLY | CALL | TRADE | BULLISH | 12/18/26 | $1180.00 | $120.0K | 17 | 20 |
About Eli Lilly and Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Following our analysis of the options activities associated with Eli Lilly and Co, we pivot to a closer look at the company's own performance.
Current Position of Eli Lilly and Co
- With a trading volume of 230,491, the price of LLY is up by 0.97%, reaching $741.5.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 44 days from now.
Professional Analyst Ratings for Eli Lilly and Co
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $880.0.
- Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Eli Lilly and Co with a target price of $1000.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $815.
- Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Eli Lilly and Co, targeting a price of $950.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $815.
- An analyst from DZ Bank has revised its rating downward to Hold, adjusting the price target to $820.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly and Co, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
